# Vascular and Metabolic Effects of Rosuvastatin

Study · id `cardio:ct-nct01660919` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01660919](<https://clinicaltrials.gov/study/NCT01660919>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01660919

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 160 participants.

## Technical summary

Registry record NCT01660919. Randomized; single masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT01660919, source copy `cardio:ctgov-nct01660919-2014-11-04`, retrieved 2026-10-31)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT01660919, source copy `cardio:ctgov-nct01660919-2014-11-04`, retrieved 2026-10-31)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01660919, source copy `cardio:ctgov-nct01660919-2014-11-04`, retrieved 2026-10-31)
- Completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01660919, source copy `cardio:ctgov-nct01660919-2014-11-04`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT01660919, source copy `cardio:ctgov-nct01660919-2014-11-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01660919-2014-11-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Vascular and Metabolic Effects of Rosuvastatin
- Condition: Hypercholesterolemia
- Intervention (Drug): placebo
- Intervention (Drug): rosuvastatin
- Lead sponsor: Gachon University Gil Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Gachon University Gil Medical Center (`cardio:org-gachon-university-gil-medical-center`)

## Provenance

Content hash: 4022db64f74af6439f90ab528439464351d9df563062f632b7f4525a9de85adf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
